Deutsche Bank raised its recommendation on Teladoc Health Inc from Hold to Buy, pointing to what it describes as an unusually low valuation and a strategic shift in the company’s BetterHelp mental health unit that could create a more sustainable growth trajectory.
The brokerage set a price target of $11 per share, which it said implies roughly 108% upside from prevailing levels.
Valuation context
Deutsche Bank noted that Teladoc is trading at about 4.2 times its 2026 EBITDA estimate. The firm said multiples at that level are typically seen among companies under financial stress, but that such a reading does not adequately account for Teladoc’s Integrated Care business, which the analysts said continues to grow.
BetterHelp strategy and market signal
The analysts pointed to management’s plan to reposition BetterHelp away from a pure direct-to-consumer model and toward services paid for through insurance. Deutsche Bank argued that insured therapy could offer a steadier and more durable revenue path over time, even though executing that transition may require an extended timeframe.
As additional context for the potential value of insured therapy businesses, Deutsche Bank cited a recent sector transaction: Universal Health Services’ agreement to buy Talkspace, a digital therapy provider focused on insurance-covered services and a competitor to BetterHelp. The bank said the implied valuation from that deal is suggestive that Teladoc’s shares might be undervalued and that BetterHelp could ultimately unlock incremental value for the company.
Brokerage rationale
Deutsche Bank summarized the upgrade as driven by three factors: Teladoc’s low valuation, the strategic shift of BetterHelp toward insured therapy services, and the benchmark set by the Talkspace acquisition. In the analysts’ words, "While this will take some time, we view this as a better business with longer term growth prospects. These insured therapy businesses are in higher demand, as evidenced by UHS' recently announced acquisition of Talkspace, a BetterHelp comp in the insured market."
Outlook
The brokerage’s move signals a view that multiple drivers - an attractive entry valuation, product mix changes at BetterHelp, and comparable M&A activity in the insured therapy space - together create a path for the stock to appreciate. The transition toward insurance-covered therapy, however, is a process and Deutsche Bank acknowledged it may take time to unfold.